Tafamidis (Vyndaqel): A Light for FAP Patients
Copyright policy )Tafamidis (Vyndaqel): A Light for FAP Patients
Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer. Tafamidis acts in a similar way to the natural hormone T4, prevents TTR amyloid fibril formation, and offers a potential alternative to liver transplantation for the treatment of patients with TTR familial amyloid polyneuropathies (TTR-FAP).
- University of Pisa Italy
Amyloid Neuropathies, Familial, Benzoxazoles, Binding Sites, Protein Structure, Tertiary, drug discovery, familial amyloid polyneuropathy, ligand design, tafamidis meglumine, transthyretin, Drug Design, Mutation, Humans, Prealbumin, Protein Binding
Amyloid Neuropathies, Familial, Benzoxazoles, Binding Sites, Protein Structure, Tertiary, drug discovery, familial amyloid polyneuropathy, ligand design, tafamidis meglumine, transthyretin, Drug Design, Mutation, Humans, Prealbumin, Protein Binding
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).21 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!